6 completed, 1 terminated, 1 unknown, 1 withdrawn. 4 Phase 3, 3 Phase 4, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 4 |
| Phase 4 | 3 | Completed 2, Terminated 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow interferon alfacon-1: new trials by email Literature Review of interferon alfacon-1 trials Research Report on interferon alfacon-1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza Interferon alfacon-1, Placebo - Influenza | Phase 1 / Phase 2 | Unknown | University Health Network, Toronto | 30 | 2010-11-01 | 2010-10-25 |
| Observational Prospective Registry of the Efficacy, Safety, and Adherence to Infergen® in Patients Infected With Hep C Infergen® (Interferon alfacon-1) - Hepatitis C | Withdrawn | Kadmon Corporation, LLC | 2009-08-01 | 2015-09-03 | ||
| Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin Infergen and ribavirin - Hepatitis C | Phase 4 | Terminated | Kadmon Corporation, LLC | 5 | 2007-02-01 | 2012-10-15 |
| Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy Interferon Alfacon-1 and Ribavirin - Hepatitis C | Phase 4 | Completed | Beth Israel Medical Center | 40 | 2005-12-01 | 2008-04-17 |
| Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin rosiglitazone - Hepatitis C | Phase 4 | Completed | Brooke Army Medical Center | 34 | 2005-10-01 | 2012-02-14 |
| Hepatitis C Treatment Naive Genotype 1 Consensus Interferon Trial consensus interferon (Interferon Alfacon-1) and ribavirin, Consensus Interferon alfa (CIFN) and ribavirin - Chronic Hepatitis C | Phase 3 | Completed | Minneapolis Veterans Affairs Medical Center | 64 | 2005-07-01 | 2014-11-21 |
| Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks - Chronic Hepatitis C | Phase 3 | Completed | Bausch Health Americas, Inc. | 144 | 2005-02-01 | 2012-06-22 |
| Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks - Chronic Hepatitis C | Phase 3 | Completed | Bausch Health Americas, Inc. | 515 | 2004-06-01 | 2019-11-25 |
| Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C Interferon alfacon-1 - Hepatitis C | Phase 3 | Completed | Astellas Pharma Inc | 2014-08-26 |
Hepatitis C (6) · Hepatitis C, Chronic (4) · Influenza, Human (1) · Insulin Resistance (1) · Orthomyxoviridae Infections (1) · Virus Diseases (1)
Bausch Health Americas, Inc. (2) · Kadmon Corporation, LLC (2) · Astellas Pharma Inc (1) · Beth Israel Medical Center (1) · Brooke Army Medical Center (1) · Minneapolis Veterans Affairs Medical Center (1) · University Health Network, Toronto (1)
United States (3) · Canada (1) · Japan (1)
Ralph T. Doyle (2) · Andrew Muir, MD (1) · Dante Morra, MD, MBA (1) · Henry C. Bodenheimer, M.D. (1) · Mitchell L Schiffman, MD (1) · Samuel B. Ho, M.D. (1) · Shane Mills, MD (1) · Stephen A Harrison, MD (1)